Hong Kong’s Foreign IPO Pipeline Expands Beyond China-Focused Firms
About 10 foreign companies from Indonesia, South Korea, Singapore, and Malaysia have filed for Hong Kong listings in 2025, marking the strongest year for international debuts since at least 2020. Johnson Chui, head of global issuer services at Hong Kong Exchanges and Clearing Ltd (HKEX), signaled this represents “the start of a structural change” in how the city attracts global capital.
What makes this shift notable: foreign firms are no longer confined to businesses with Greater China exposure. “The nexus is broadening,” Chui told Reuters. “In the past it was more: do you have business exposure in Greater China? But now, there are very successful examples for companies that have no business at all in this part of the world.”
The foreign IPO hopefuls span technology, consumer goods, and financial services sectors—a diversification that signals Hong Kong’s appeal as a global capital-raising venue, not just a China gateway.
The Numbers: How Hong Kong Compares to Chinese IPO Dominance
While 10 foreign listings sound impressive, context matters for retail investors tracking regional capital flows.
- Chinese and Hong Kong domestic firms dominated 2025: 110 companies raised US$36.4 billion via IPO according to LSEG data
- Foreign firms are a fraction: 10 international debuts would represent far less capital than domestic activity
- Hong Kong remains the world’s top IPO market: Last year, HKEX hosted 115 IPO deals raising US$37.4 billion total—dwarfing most other global exchanges
- 2025 marks a turning point: This would be the city’s best year for international debuts since at least 2020, signaling renewed appetite for overseas listings
Malaysian Firms Leading the Charge: Teleport and Capital A
Two Malaysian companies are actively evaluating Hong Kong as a listing venue, bringing Southeast Asian representation to HKEX’s expanding international pipeline.
Teleport, a Malaysian logistics firm, confirmed Hong Kong is among the venues it is evaluating for a public listing. “Our long-term roadmap includes a public listing,” CEO Pete Chareonwongsak told Reuters. “We are keeping our options open.” This signals Malaysian companies are no longer defaulting to Bursa Malaysia as the sole listing destination.
Capital A, the Malaysian branding-to-logistics group, appears in LSEG’s preliminary 2026 Hong Kong IPO pipeline alongside 11 other foreign firms. Capital A’s potential Hong Kong debut would be a significant test case for whether Bursa-listed companies (or their spin-offs) see greater value-creation opportunities offshore.
What This Means for Bursa Malaysia Investors
The Hong Kong IPO surge creates both opportunities and headwinds for Bursa Malaysia participants.
Potential capital diversion risk: If Malaysian companies increasingly choose Hong Kong over Bursa for IPOs, it could reduce the pipeline of new listings on the local exchange. This matters for retail investors seeking diversification within local stocks.
Regulatory and liquidity questions: Bursa Malaysia has implemented reforms to attract listings, but Bursa-listed firms seeking a “second listing” in Hong Kong may face dual-compliance costs. Investors holding Bursa stocks tied to companies pursuing concurrent or sequential dual listings should monitor announcement dates and regulatory filings.
Regional capital flows shift: As foreign capital increasingly flows to Hong Kong IPOs, it may reduce regional liquidity for Bursa Malaysia counters. This is worth monitoring for investors with exposure to mid-cap Malaysian companies competing for capital.
The Blockbuster Deal: Syngenta Group’s US$10 Billion Play
Swiss-based agrochemicals and seeds company Syngenta Group plans a Hong Kong listing of up to US$10 billion in the second half of 2025, according to Reuters reporting from February citing sources. This deal alone would be transformational for HKEX’s ability to attract mega-cap international listings.
At US$10 billion, a Syngenta listing would represent roughly 27% of the entire US$36.4 billion raised by Chinese and Hong Kong domestic firms in 2025—demonstrating that a single large international deal can significantly shift regional capital-raising momentum.
For Malaysian investors, Syngenta’s move signals that HKEX is now competing directly with Singapore, London, and New York for tier-one international listings. This competitive pressure may force Bursa Malaysia to accelerate its own listing reforms and incentive structures to retain local companies.
Other Foreign Firms Considering Hong Kong: Biotech and Blockchain Focus
Beyond Malaysian firms, several international companies are in preliminary discussions with HKEX about possible listings.
- Engine Biosciences (Singapore-based biotech) is considering a Hong Kong listing
- NiKang Therapeutics (U.S.-based biotech) is exploring options in the city
- Blockdaemon (U.S. blockchain infrastructure firm) appears in 2026 pipeline
- Allergy Therapeutics (British biopharmaceutical) is also listed as a potential 2026 Hong Kong IPO candidate
According to LSEG data compiled on May 4, there are at least 12 foreign companies in Hong Kong’s preliminary 2026 IPO pipeline. However, these are early-stage discussions, and plans frequently change. Engine Biosciences declined to comment; NiKang did not respond—standard silence from firms in confidential pre-IPO planning.
Why Biotech and Deep Tech Are Flocking to Hong Kong
The concentration of biotech and blockchain firms in Hong Kong’s foreign IPO pipeline reflects strategic positioning.
Asian biotech hub: Hong Kong offers biotech companies access to Asia-Pacific capital, Chinese institutional investors (with no China business required), and regulatory credibility absent from lesser-developed exchanges.
Crypto-friendly narrative: Hong Kong has positioned itself as more open to blockchain and digital assets compared to U.S. and European regulators. Blockdaemon’s pipeline inclusion signals growing appetite for crypto infrastructure IPOs in the region.
Bursa Malaysia consideration: Malaysian biotech firms (if any reach IPO stage) may face a strategic choice: seek capital on Bursa Malaysia’s smaller investor base, or pursue Hong Kong’s deeper pools of institutional capital.
How This Reshapes Regional Capital Markets Strategy
The structural shift Chui described—broadening beyond China exposure—has three major implications for Malaysian retail investors.
First, Hong Kong is becoming a genuine global IPO venue. It’s no longer a secondary choice for Chinese firms needing offshore capital. Syngenta, a Swiss company, choosing Hong Kong over London or New York speaks to HKEX’s improved competitive positioning and trading ecosystem.
Second, Malaysian companies have optionality. Teleport and Capital A’s exploration of Hong Kong listings reflects a new era where Malaysian entrepreneurs consider regional IPO hubs rather than defaulting to Bursa Malaysia. This competitive pressure may ultimately benefit retail investors through improved disclosure standards and governance practices—as Bursa Malaysia must compete for listings.
Third, foreign capital into Hong Kong IPOs may reduce regional liquidity. If institutional investors (including Malaysian EPF and PRS funds) allocate more to Hong Kong IPOs, it could reduce capital available for Bursa Malaysia growth companies. This argues for diversifying IPO exposure between Bursa and Hong Kong for forward-thinking retail investors.
What Should Retail Investors Watch Right Now?
For investors on Bursa Malaysia, several catalysts warrant close monitoring over the next 6-12 months.
- Syngenta’s IPO timeline: If the US$10 billion listing completes in H2 2025, it will set a new benchmark for mega-cap international debuts on HKEX, potentially triggering a cascade of similar-scale listings
- Teleport’s listing announcement: When Teleport announces its venue choice (Bursa, Hong Kong, or concurrent dual listing), it signals Malaysian investor appetite for logistics IPOs at home versus offshore
- Capital A’s 2026 pipeline progress: Any formal announcement from Capital A about a Hong Kong listing would be material for existing shareholders and potential IPO participants
- Bursa Malaysia’s competitive response: Watch for new listing incentives, accelerated approvals, or regulatory changes from Bursa Malaysia as it responds to HKEX’s foreign IPO success
- Malaysian biotech and tech IPO pipeline: If any local biotech or blockchain firms announce Hong Kong IPO plans, it suggests Bursa Malaysia is losing competitiveness in high-growth sectors
For IPO investing in Malaysia and the region, this shift underscores the importance of comparing multiple listing venues and understanding the structural advantages (liquidity, investor base, currency exposure) of each.
Key Takeaways for Malaysian Investors
- Hong Kong attracted 10 foreign company IPOs in 2025, marking its best year for international debuts since 2020, signaling a structural shift toward non-China-focused listings
- Two Malaysian firms—Teleport and Capital A—are actively evaluating Hong Kong listings, suggesting Bursa Malaysia faces new competition for IPO-stage companies
- Syngenta Group’s planned US$10 billion Hong Kong listing will set a new benchmark for mega-cap international debuts and likely trigger more global firms to choose HKEX
- Biotech and blockchain firms dominate the foreign IPO pipeline, reflecting Hong Kong’s positioning as Asia’s deep-tech capital-raising hub
- Malaysian retail investors should monitor Bursa Malaysia’s competitive response—new listing incentives or regulatory changes may arrive if domestic companies continue exploring offshore venues
The Hong Kong IPO rebound is reshaping how Asian capital markets compete for international listings. For Bursa Malaysia investors, this means heightened competition for growth-stage Malaysian companies and potential shifts in regional capital flows. Stay alert to announcements from Teleport, Capital A, and other potential listing candidates—these decisions will signal whether Bursa Malaysia can retain its role as Southeast Asia’s primary capital-raising venue, or if Hong Kong’s structural advantages are pulling listings offshore.
Always conduct your own research and consult a licensed financial advisor before making investment decisions. This article is for informational purposes and does not constitute financial advice.
Source: View Original Article — The content is based on the original publisher. Refer to the original content for accurate info. Contact us for any changes.
Related Resources from Dexter Chia
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.
Want to invest in Bursa Malaysia or US markets? Contact Dexter Chia, an AI Driven Remisier who has 2,200+ clients at Malacca Securities Sdn Bhd (M+ Online / M+ Global). M+ Global Invitation Code: UBZQ | WhatsApp: +60169059789 | Why Choose Dexter?